Cargando…

Pathogen-driven gene expression patterns lead to a novel approach to the identification of common therapeutic targets

Developing a common medication strategy for disease control and management could be greatly beneficial. Investigating the differences between diseased and healthy states using differentially expressed genes aids in understanding disease pathophysiology and enables the exploration of protein-drug int...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Mohammad Uzzal, Ferdous, Nadim, Reza, Mahjerin Nasrin, Ahammad, Ishtiaque, Tiernan, Zachary, Wang, Yi, O’Hanlon, Fergus, Wu, Zijia, Sarker, Shishir, Mohiuddin, A. K. M., Das, Keshob Chandra, Keya, Chaman Ara, Salimullah, Md.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726901/
https://www.ncbi.nlm.nih.gov/pubmed/36473896
http://dx.doi.org/10.1038/s41598-022-25102-8
Descripción
Sumario:Developing a common medication strategy for disease control and management could be greatly beneficial. Investigating the differences between diseased and healthy states using differentially expressed genes aids in understanding disease pathophysiology and enables the exploration of protein-drug interactions. This study aimed to find the most common genes in diarrhea-causing bacteria such as Salmonella enterica serovar Typhimurium, Campylobacter jejuni, Escherichia coli, Shigella dysenteriae (CESS) to find new drugs. Thus, differential gene expression datasets of CESS were screened through computational algorithms and programming. Subsequently, hub and common genes were prioritized from the analysis of extensive protein–protein interactions. Binding predictions were performed to identify the common potential therapeutic targets of CESS. We identified a total of 827 dysregulated genes that are highly linked to CESS. Notably, no common gene interaction was found among all CESS bacteria, but we identified 3 common genes in both Salmonella-Escherichia and Escherichia-Campylobacter infections. Later, out of 73 protein complexes, molecular simulations confirmed 5 therapeutic candidates from the CESS. We have developed a new pipeline for identifying therapeutic targets for a common medication strategy against CESS. However, further wet-lab validation is needed to confirm their effectiveness.